Staphylococcus aureus colonisation and bacteraemia in persons infected with human immunodeficiency virus: a dynamic interaction with the host.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Staphylococcus aureus colonisation and bacteraemia in persons infected with human immunodeficiency virus: a dynamic interaction with the host.

J Chemother. 1995 Jul;7 Suppl 3:19-28. Unique Identifier : AIDSLINE MED/96192761
Craven DE; Department of Medicine, Boston University School of Medicine,; Boston City Hospital, MA 02118, USA.

Abstract: Bacterial infections are common in persons with symptomatic disease caused by human immunodeficiency virus (HIV). Colonisation and infection with Staphylococcus aureus is present in 30% to 50% of persons with HIV disease. Risk factors for bacteraemia due to S. aureus include nasal colonisation, advanced HIV disease with CD4+ lymphocyte count < 100/mm3, prior hospitalisations, neutropenia, skin lesions, intravenous drug use, and the presence of invasive devices, such as intravenous catheters. Some antibiotics may increase the risk of S. aureus nasal colonisation, and others such as trimethoprim-sulphamethoxazole and rifabutin may reduce colonisation and disease. Preliminary data suggest that mupirocin may decrease nasal colonisation with S. aureus, but the optimal regimen, duration of effect, use, and concerns about resistance, need further evaluation. Recent data suggest that bacterial infection may accelerate the progression of HIV disease. The presence of bacterial superantigens or cytokines, such as the exotoxins present in many strains of S. aureus have been shown to induce HIV production in human peripheral blood mononuclear leukocyte cultures in vitro, although the precise mechanism is unclear. Thus, HIV infection may increase the risk of S. aureus colonisation and disease and, in turn, infection or colonisation with S. aureus may accelerate the progression of HIV disease to AIDS.

Keywords: Bacteremia/*ETIOLOGY Human HIV Infections/COMPLICATIONS/*IMMUNOLOGY Immune Tolerance Risk Factors Staphylococcal Infections/*ETIOLOGY JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL
960830
M9681178

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .